Eckard Weber Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Eckard Weber ADYX stock SEC Form 4 insiders trading

Eckard has made over 1 trades of the Adynxx stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 11,969 units of ADYX stock worth $11,011 on 4 January 2016.

The largest trade he's ever made was exercising 11,969 units of Adynxx stock on 4 January 2016 worth over $11,011. On average, Eckard trades about 1,710 units every 0 days since 2015. As of 4 January 2016 he still owns at least 356,688 units of Adynxx stock.

You can see the complete history of Eckard Weber stock trades at the bottom of the page.

Eckard Weber biography

Dr. Eckard Weber M.D. serves as Director of the Company. Dr. Eckard Weber is a partner at Domain Associates LLC, where he specializes in creating companies around promising new pharmaceutical products. In addition to serving on the Adynxx board of directors, Eckard currently serves as chairman of the board at Ocera Therapeutics and Tragara Pharmaceuticals. He has been founding CEO of multiple biopharmaceutical companies in the Domain portfolio, including Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia, Domain Anti Bacterial Acquisition Corporation, NovaCardia, Novacea, Novalar Pharmaceuticals, Ocera Therapeutics, Orexigen Therapeutics, Sonexa Therapeutics, Syndax Pharmaceuticals, Tobira Therapeutics and Tragara Pharmaceuticals. Eckard was chairman of a number of Domain portfolio companies until their successful exit, including Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005), Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), Calixa (sold to Cubist Pharmaceuticals, 2009). He was also a board member of Conforma Therapeutics (sold to Biogen-IDEC, 2006), Cabrellis Pharmaceuticals (sold to Pharmion, 2006) and Tobira Therapeutics (sold to Allergan, 2016). Previously, Eckard was a tenured professor of pharmacology at the University of California at Irvine. He has more than 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. He is the inventor or co-inventor of numerous patents and patent applications, and he has published more than 130 papers in scientific periodicals. Eckard completed his Abitur from Kolping Kolleg, Friedrichshafen, Germany and his M.D. from the University of Ulm Medical School, Germany. He received his postdoctoral training in neuroscience at Stanford University Medical School.

What's Eckard Weber's mailing address?

Eckard's mailing address filed with the SEC is C/O ADYNXX, INC., 100 PINE ST., STE. 500, SAN FRANCISCO, CA, 94111.

What does Adynxx do?

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Adynxx executives and stock owners

Adynxx executives and other stock owners filed with the SEC include:

• Richard Orr,
  Pres, CEO, Principal Financial Officer & Director
• Dr. Julien Mamet Ph.D.,
  Founder, Chief Scientific Officer & Director
• Eckard Weber,
  Director
• Matthew Ruth,
  Director
• Gregory Flesher,
  Director
• Stan Abel,
  Director
• Donald Manning,
  Chief Medical Officer
• Julien Mamet,
  Chief Scientific Officer, Director
• Rick Orr,
  Chief Executive Officer, Principal Financial Officer, Director
• Dennis Podlesak,
  Chairman of the Board
• Kimberley Hebert,
  Sr. Director of Clinical Operations
• Dina Gonzalez,
  Principal Accounting Officer & Sr. VP of Fin.
• William Martin,
  Exec. VP of Corp. Devel. & Operations